Corporates Johnson & Johnson, Eli Lilly and Pharmstandard jointly hold more than 45% of the IBD drug developer, which has raised $67m since 2006.

Celgene has contributed an undisclosed amount to the $24m in funding Zymeworks just raised, as part of a collaboration and licensing partnership.

Korea-headquartered drug producer Hanmi Pharmaceutical will back biotech and pharmaceutical startups through its newly formed Hanmi Ventures subsidiary.

Novartis-backed eye therapy developer GenSight filed for a $100m offering in the US a year ago, only to withdraw in November.

The genomic medicine company initially raised $50m in an offering that enabled WuXi PharmaTech to exit, before its stock rose significantly post-IPO.

BGF Ventures, funded by several financial services firms, has helped the doctor sourcing platform close about $7m in funding.

The preventative health app developer was only incorporated two months ago but has already raised $15m in an IDG Ventures-backed series A round.

IBF, backed by Biogen and Medison, has led an $8m series A round for small-molecule drug developer Vidac Pharma, which has an actinic keratosis treatment in phase 2 trials.

Breathalyser technology developer Spirometrix has secured $17.4m in the Fosun Pharma-led first tranche of a round also backed by NGK Spark Plug.